Can-Fite BioPharma (CANF) EBIT (QoQ) (2014 - 2023)
Powered by 
Analysis
Can-Fite BioPharma (CANF) EBIT (QoQ) (2014 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.12 Bn | 628.36 Bn | 17.26 Bn |
| 2 | AbbVie | 445.86 Bn | 439.29 Bn | 12.70 Bn |
| 3 | Merck | 362.13 Bn | 354.99 Bn | 12.21 Bn |
| 4 | Novartis Ag | 268.88 Bn | 261.19 Bn | 11.24 Bn |
| 5 | Pfizer | 156.96 Bn | 145.26 Bn | 10.94 Bn |
| 6 | Sanofi | 52.26 Bn | 44.88 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.98 Bn | 42.98 Bn | - |
| 8 | Incyte | 25.13 Bn | 20.59 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.56 Bn | 18.90 Bn | 683.80 Mn |
| 10 | Can-Fite BioPharma | 1.80 Mn | -1.19 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 1.66% |
| Sep 30, 2023 | -4.54% |
| Jun 30, 2023 | 34.22% |
| Mar 31, 2023 | -129.44% |
| Dec 31, 2022 | 54.06% |
| Sep 30, 2022 | -24.30% |
| Jun 30, 2022 | 12.66% |
| Mar 31, 2022 | 41.16% |
| Dec 31, 2021 | -14.76% |
| Sep 30, 2021 | -12.03% |
| Jun 30, 2021 | -44.31% |
| Mar 31, 2021 | 38.90% |
| Dec 31, 2020 | -43.32% |
| Sep 30, 2020 | 35.29% |
| Dec 31, 2019 | -65.21% |
| Sep 30, 2019 | 55.81% |
| Jun 30, 2019 | -469.14% |
| Mar 31, 2019 | 168.36% |
| Dec 31, 2018 | -488.66% |
| Sep 30, 2018 | 112.52% |